Synaptogenix Announces Peer-Reviewed Publication Of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, And Persistent Benefits Of Bryostatin-1 in Advanced Alzheimer's Disease
Portfolio Pulse from Benzinga Newsdesk
Synaptogenix, Inc. (NASDAQ:SNPX) has announced the publication of a peer-reviewed paper detailing the results of a Phase 2 clinical trial for Bryostatin-1, a drug developed for the treatment of Alzheimer's disease. The trial demonstrated statistically significant benefits of Bryostatin-1 in advanced Alzheimer's patients, with no significant cognitive decline observed over a 10-month period. The trial was sponsored by the National Institute on Aging (NIA) and the National Cancer Institute (NCI), both part of the NIH.
September 26, 2023 | 1:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The announcement of positive Phase 2 trial results for Synaptogenix's Alzheimer's drug Bryostatin-1 could potentially boost investor confidence and positively impact the company's stock price in the short term.
The announcement of positive trial results is typically seen as a positive development for biopharmaceutical companies, as it indicates progress in the drug development process and increases the likelihood of eventual regulatory approval. This could potentially attract more investors to the company, leading to an increase in demand for the stock and a rise in its price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100